Last updated: February 26, 2026
What is the Drug Associated with NDc 68084-0549?
NDc 68084-0549 corresponds to Trazodone Hydrochloride tablet, indicated primarily for the treatment of major depressive disorder, anxiety disorders, and as a sleep aid. Trazodone is marketed under brand names such as Desyrel and Oleptro.
Market Size and Segment Dynamics
Global and U.S. Market
- The global antidepressant market was valued at approximately USD 16.2 billion in 2021, with a compound annual growth rate (CAGR) of around 2.5% to 3% projected through 2028 [1].
- The U.S. accounts for roughly 50% of this market, driven by high prescription rates for depression, anxiety, and off-label uses such as sleep disorders.
Trazodone's Role
- Trazodone constitutes about 10-12% of overall antidepressant prescriptions in the U.S., primarily as a sleep aid and for off-label depression management [2].
- The drug's prescribing volume increased during the COVID-19 pandemic, reflecting heightened mental health awareness and sleep disorder diagnoses.
Competition
- Main competitors include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants.
- Trazodone’s off-label use for insomnia sustains steady demand, though patent expiry and generic availability pressure prices downward.
Pricing Overview
Existing Price Benchmarks
| Formulation |
Average Wholesale Price (AWP) per unit |
Typical Retail Price (TRP) |
| Trazodone 50 mg |
USD 0.10 |
USD 0.20 |
| Trazodone 100 mg |
USD 0.15 |
USD 0.30 |
- The pharmacy acquisition cost for generics is approximately half these figures.
- Insurance rebates and discounts further reduce the effective price for payers.
Price Developments
- Generic trazodone 50 mg and 100 mg tablets have seen price stability over the past five years.
- No recent substantial price hikes observed unless tied to formulation improvements or specific formulations (sustained release, combination products).
Regulatory and Patent Status
- Trazodone's original patent expired in 2002; multiple generics entered the market by 2003.
- Recent formulations like extended-release variants (e.g., Oleptro) have patent protections extending into 2025–2027, but these do not affect immediate generic pricing.
Market Trends and Drivers
- Increasing mental health awareness and depression treatment rates sustain demand.
- Off-label prescribing for sleep continues to support steady volume.
- Cost-efficiency drives healthcare providers toward generic formulations.
- The COVID-19 pandemic increased sleep aid prescriptions, boosting demand temporarily.
Price Projection Outlook
| Year |
Estimated Average Wholesale Price (USD) per unit |
Comments |
| 2023 |
USD 0.10 - 0.12 |
Stable, driven by generic competition |
| 2024 |
USD 0.10 - 0.12 |
Continued price stability expected |
| 2025 |
USD 0.12 - 0.14 |
Slight increase anticipated, possibly due to supply chain adjustments or new formulations |
| 2026 |
USD 0.13 - 0.15 |
Prices may plateau or decrease marginally as patent protections for new formulations expire |
Key Considerations for Investment and R&D
- Market share shifts towards newer antidepressants with improved efficacy and tolerability could influence demand.
- Pricing is constrained by generic competition, limiting potential profit margins.
- Developing branded formulations may be viable before patent expiry of extended-release options.
Summary
Trazodone's market remains stable, with modest growth driven by off-label sleep aid use and antidepressant prescriptions. Pricing is near a floor due to widespread generics, with minimal upward pressure. Industry consolidates around cost-effective prescribing patterns, and future price improvements hinge on formulation innovations or shifts in prescribing trends.
Key Takeaways
- The drug’s market is mature, with limited price elasticity.
- Generic competition dominates, capping maximum prices.
- Demand persists owing to off-label uses and mental health needs.
- Price projections are steady, with minor possible increases aligned with formulation development.
- Investment should focus on potential formulation innovations rather than price leverage.
FAQs
Q1: Will the price of trazodone increase after patent expiry of extended-release formulations?
A1: Likely not significantly. Price reductions from generic competition have historically limited increases.
Q2: How does the off-label use for sleep influence market size?
A2: It sustains consistent demand, especially among patients seeking non-benzodiazepine sleep aids.
Q3: Are there significant regulatory hurdles to new formulations of trazodone?
A3: No significant hurdles exist if they are incremental modifications; major reforms require extensive clinical testing.
Q4: What factors could disrupt current pricing stability?
A4: Supply chain issues, regulatory changes, or large-scale shifts in prescribing guidelines could influence prices.
Q5: How does market competition from newer drugs affect trazodone pricing?
A5: Competition from newer antidepressants with improved side effect profiles pressures price even for generics.
References
- Statista. (2022). Global antidepressants market size. https://www.statista.com
- IMS Health. (2021). Prescription trends in mental health medications. https://www.imshealth.com
